Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 1 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,292 | -12.0% | 237,090 | +9.7% | 0.00% | 0.0% |
| Q2 2023 | $1,468 | +235.2% | 216,200 | +147.4% | 0.00% | +100.0% |
| Q1 2023 | $438 | +67.8% | 87,400 | +63.4% | 0.00% | – |
| Q4 2022 | $261 | -100.0% | 53,500 | -58.2% | 0.00% | -100.0% |
| Q3 2022 | $1,844,000 | -18.6% | 127,900 | -14.6% | 0.00% | 0.0% |
| Q2 2022 | $2,266,000 | +109.6% | 149,800 | +64.6% | 0.00% | +200.0% |
| Q1 2022 | $1,081,000 | -32.4% | 91,000 | -7.7% | 0.00% | -50.0% |
| Q4 2021 | $1,598,000 | +64.1% | 98,600 | +206.2% | 0.00% | +100.0% |
| Q1 2021 | $974,000 | +19.8% | 32,200 | +23.8% | 0.00% | 0.0% |
| Q4 2019 | $813,000 | -55.9% | 26,000 | -63.2% | 0.00% | -50.0% |
| Q3 2019 | $1,842,000 | +92.7% | 70,700 | +69.1% | 0.00% | +100.0% |
| Q2 2019 | $956,000 | – | 41,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |